SMI Protein Microarray: SARS-CoV-2, SARS-CoV, MERS-CoV, & Influenza.

The SMI Protein Array is a flexible platform that detects serological antibodies related to pandemic COVID-19 disease, allowing the immune response against three disease-causing coronaviruses and the influenza virus to be analyzed.

SMI Protein Microarray: SARS-CoV-2, SARS-CoV, MERS-CoV, & Influenza.

The SMI Protein Array is a flexible platform that detects serological antibodies, allowing the immune response against three disease-causing coronaviruses and the influenza virus to be analyzed.

Economic screening for antibodies to pandemic SARS-CoV-2 and other closely related viruses.

The SMI Protein Microarray contains 14 identical sub-arrays of full-length viral proteins, each printed in triplicate, and is highly sensitive, detecting as low as 50 pg of anti-S antibody in human serum. The array allows simultaneous detection of IgG and IgM (multiplexing), and provides a clear profile of each patient’s immune response to infection by the three closely-related coronavirus strains and by influenza.  The direct comparison of responses to infection from SARS-CoV2, MERS–CoV and SARS-CoV allows false negatives or non-specific binding to be carefully evaluated.

SMI microarray x14 sample layout.

SMI-Microarray-Layout-CDI-Labs-SARS-MERS-INFLUENZA
Example-Minichip-Layout-for-CDI-Labs-SARS-CoV-2-COVID-19-Microarray-Peptides-Protein

Download the protocols followed by our SMI array analysis service.

CDI Antygen™ SMI arrays can be purchased directly or provided as a complete analysis service.

SMI Protein Microarray Technical Datasheet & COA

SMI Protein Microarray Full Protocol & Technical Manual

SMI microarray technical details.

Multi-viral: Includes S and N proteins from SARS-CoV-2, SARS-CoV, MERS-CoV and influenza. Proteins are purified and printed in triplicate. Each microarray contains 14 identical sub-arrays produced by contact printing.

Multiplexed: Simultaneously detect serum IgG/IgM and profile the immune responses against several viral proteins.

Accurate: Direct comparison of proteins from SARS-CoV-2, SARS-CoV, and MERS-CoV is possible for each patient sample on a single array; false negatives or non-specific binding can be evaluated. The combination of multiple markers on each array also contributes to the specificity and accuracy of the readout.

Flexible: As new SARS-CoV-2 mutations are discovered in clinical samples, CDI can add these mutated proteins directly onto the SMI Protein Array to provide a deeper look into how these new mutations impact disease. For clinical applications, the SMI Protein Array is a flexible platform for discovering and then combining different markers to help advance disease diagnosis, prognosis and classify disease severity.

Sensitive: Using only 1 microliter of serum for the assay (less than a drop of blood) considerable data can be acquired and subjected to bioinformatic analysis for research, clinical, and epidemical use.

Specific: The SMI Protein Array will accelerate the development of highly specific biological products for disease detection and other medical uses.

Experimental procedure for serologic antibody detection.

SMI-Microarray-Analysis-Method-for-Antibodies-CDI-Labs-SARS-MERS-INFLUENZA

SMI microarray additional information.

Format/Content: 14 sub-arrays (2X7 format). Each sub-array contains the following full length proteins: SARS-CoV-2 (S-protein, S-frag protein, N-protein); SARS-CoV (S-frag protein, N-protein); MERS-CoV (S-protein, S-frag protein, N-protein); Influenza (H1N1-HA protein, H3N2-HA protein, FluB-HA protein).

Manufacture: Pin-printing on aldehyde glass; fluorescence detection.

Protein Expression System: Baculovirus.

Controls: BSA, buffer, Poly-L-lysine, Cy3, Cy5, Anti-human Ab mix, and Anti-human IgG, Anti-human IgM and anti-human IgA.

Storage: -80˚C in sealed bags with plastic slide holders and desiccant.

Example data from COVID-19 patient serum versus healthy controls.

SMI protein microarray service details & data deliverables.

A typical SMI microarray service involves case and control serum samples diluted 1:1000 and reacted with individual microarrays with blocking buffer. After incubation, samples are stained for one or two desired fluorescent secondary detection antibodies (ie IgG / IgA / IgM). Arrays are scanned and raw TIF images are created using Molecular Devices Genepix microarray scanners. Spots are then aligned to CDI library (.gal) files, and spot readings are output as raw Genepix results (.gpr) files. These raw results are then delivered both as .gpr files and combined data tables.

SMI microarray service sample requirements.

Human serum or plasma: Send two 10μL aliquots per sample.

Antibody isolates: At least 3μg per sample (conc. >0.1mg / mL).

Human (CSF) cerebrospinal fluid: At least 1.5mL per sample.

Protein / peptide / small molecule: At least 3μg per sample.

Other fluids: Please contact us.

Sample shipping & sample return.

We will include shipping details in your quote – you must cover the cost of shipping samples to CDI. Typically, after you receive your report, CDI keeps the remaining samples for two months and then disposes of them. When shipping to us, please let us know if you want the remaining samples returned after the study is complete. We will charge for return shipping.

Contact us to learn more.

Fields marked with an * are required
First Name
Last Name
Company or Institution
Email
Brief Project Description: